Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gonadorelin Acetate

FDA-approved product (injectable, injection), marketed as Lutrepulse Kit, Factrel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Gonadorelin Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Gonadorelin Acetate. Its therapeutic class is shown instead.

WHO therapeutic group
Gonadotropin-releasing hormones; Tests for fertility disturbances
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Gonadorelin Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gonadorelin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients

    NCT07460752 · start 2026-05-22

    Registered record
    Registry ID
    NCT07460752
    Conditions
    Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Locally Advanced Hormone Receptor-Positive Breast Carcinoma
    Interventions
    Biospecimen Collection; Goserelin Acetate; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-05-22
    Completion
    2029-09-26
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Locally Advanced Hormone Receptor-Positive Breast Carcinoma
    InterventionBiospecimen Collection; Goserelin Acetate; Questionnaire Administration
    PhasePhase 2
    Registry statusRecruiting

  • Effect of a GnRH Analog on Hepatic Steatosis

    NCT06523530 · start 2024-11-26

    Registered record
    Registry ID
    NCT06523530
    Conditions
    Metabolic Dysfunction-Associated Steatotic Liver Disease; Nonalcoholic Fatty Liver; Endometriosis
    Interventions
    Goserelin Acetate 3.6 mg inj, implant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2024-11-26
    Completion
    2027-10
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic Dysfunction-Associated Steatotic Liver Disease; Nonalcoholic Fatty Liver; Endometriosis
    InterventionGoserelin Acetate 3.6 mg inj, implant
    PhasePhase 4
    Registry statusActive not recruiting

  • Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

    NCT06348264 · start 2024-10-10

    Registered record
    Registry ID
    NCT06348264
    Conditions
    Salivary Gland Neoplasm Duct
    Interventions
    Rezvilutamide; Leuprolide Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-10-10
    Completion
    2031-03-30
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSalivary Gland Neoplasm Duct
    InterventionRezvilutamide; Leuprolide Acetate
    PhasePhase 2
    Registry statusRecruiting

  • Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

    NCT06490328 · start 2024-05-30

    Registered record
    Registry ID
    NCT06490328
    Conditions
    Advanced Prostate Cancer
    Interventions
    DKF-MA102
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2024-05-30
    Completion
    2026-03-09
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Prostate Cancer
    InterventionDKF-MA102
    PhasePhase 3
    Registry statusCompleted

  • Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

    NCT06369610 · start 2024-04-22

    Registered record
    Registry ID
    NCT06369610
    Conditions
    Oligometastatic Prostate Carcinoma; Prostate Adenocarcinoma
    Interventions
    Abiraterone Acetate; Biospecimen Collection; Computed Tomography; Gonadotropin-releasing Hormone Analog; Magnetic Resonance Imaging; Positron Emission Tomography; Questionnaire Administration; Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-04-22
    Completion
    2027-04-22
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOligometastatic Prostate Carcinoma; Prostate Adenocarcinoma
    InterventionAbiraterone Acetate; Biospecimen Collection; Computed Tomography; Gonadotropin-releasing Hormone Analog +4 more
    PhasePhase 2
    Registry statusRecruiting

  • Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone（GnRH）Antagonist Protocol in Women Undergoing IVF

    NCT06023602 · start 2024-02-27

    Registered record
    Registry ID
    NCT06023602
    Conditions
    Infertility
    Interventions
    Generic cetrorelix acetate; Reference cetrorelix acetate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-02-27
    Completion
    2025-12-01
    Enrolment
    1,338

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionGeneric cetrorelix acetate; Reference cetrorelix acetate
    PhaseNot applicable
    Registry statusRecruiting

  • Evaluate the Efficacy and Safety of DWJ108J

    NCT06025409 · start 2023-08-01

    Registered record
    Registry ID
    NCT06025409
    Conditions
    Central Precocious Puberty
    Interventions
    Leuprolide Acetate 11.25 MG/ML
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-08-01
    Completion
    2025-08-31
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Precocious Puberty
    InterventionLeuprolide Acetate 11.25 MG/ML
    PhasePhase 3
    Registry statusUnknown

  • Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles

    NCT05767086 · start 2023-03-15

    Registered record
    Registry ID
    NCT05767086
    Conditions
    Infertility
    Interventions
    Gonadotropin releasing hormone antagonist (Cetrotide); Medroxyprogesterone Acetate (Tarlusal); Dydrogesterone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-03-15
    Completion
    2024-09-30
    Enrolment
    297

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionGonadotropin releasing hormone antagonist (Cetrotide); Medroxyprogesterone Acetate (Tarlusal); Dydrogesterone
    PhaseNot applicable
    Registry statusCompleted

  • Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

    NCT05605964 · start 2023-01-28

    Registered record
    Registry ID
    NCT05605964
    Conditions
    Prostate Cancer
    Interventions
    Relugolix; Leuprolide Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-01-28
    Completion
    2024-12-31
    Enrolment
    387

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRelugolix; Leuprolide Acetate
    PhasePhase 3
    Registry statusCompleted

  • A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

    NCT04961996 · start 2021-08-27

    Registered record
    Registry ID
    NCT04961996
    Conditions
    Early Breast Cancer
    Interventions
    Giredestrant; Physician's Choice of Endocrine Therapy; LHRH Agonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-08-27
    Completion
    2033-09-30
    Enrolment
    4,170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly Breast Cancer
    InterventionGiredestrant; Physician's Choice of Endocrine Therapy; LHRH Agonist
    PhasePhase 3
    Registry statusActive not recruiting

  • Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI

    NCT04727684 · start 2020-08-22

    Registered record
    Registry ID
    NCT04727684
    Conditions
    In Vitro Fertilization; Infertility; Intracytoplasmic Sperm Injection; Polycystic Ovary Syndrome
    Interventions
    Triptorelin acetate; Cetrorelix; recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin; Human Chorionic Gonadotropin (hCG)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-08-22
    Completion
    2022-05-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIn Vitro Fertilization; Infertility; Intracytoplasmic Sperm Injection; Polycystic Ovary Syndrome
    InterventionTriptorelin acetate; Cetrorelix; recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin; Human Chorionic Gonadotropin (hCG)
    PhasePhase 4
    Registry statusCompleted

  • Neurobiology of Bulimia Nervosa

    NCT04225221 · start 2020-02-24

    Registered record
    Registry ID
    NCT04225221
    Conditions
    Bulimia Nervosa
    Interventions
    Estradiol; Micronized progesterone; Leuprolide Acetate; Placebo Oral Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-02-24
    Completion
    2022-04-04
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBulimia Nervosa
    InterventionEstradiol; Micronized progesterone; Leuprolide Acetate; Placebo Oral Capsule
    PhasePhase 2
    Registry statusCompleted

  • Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model

    NCT04051320 · start 2020-01-02

    Registered record
    Registry ID
    NCT04051320
    Conditions
    Perinatal Depression; Post Partum Depression; Depression, Postpartum; Depression
    Interventions
    Leuprolide Acetate 3.75 MG/ML; Estradiol 2 Mg tablet; Micronized progesterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-01-02
    Completion
    2022-07-19
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerinatal Depression; Post Partum Depression; Depression, Postpartum; Depression
    InterventionLeuprolide Acetate 3.75 MG/ML; Estradiol 2 Mg tablet; Micronized progesterone
    PhasePhase 2
    Registry statusCompleted

  • Coasting Versus Antagonist Protocol in Patients at High Risk of OHSS

    NCT03996434 · start 2019-07-01

    Registered record
    Registry ID
    NCT03996434
    Conditions
    Ovarian Hyperstimulation Syndrome
    Interventions
    Gonadotropin; Antagonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-07-01
    Completion
    2019-11-20
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Hyperstimulation Syndrome
    InterventionGonadotropin; Antagonist
    PhasePhase 4
    Registry statusCompleted

  • REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

    NCT03951831 · start 2019-05-16

    Registered record
    Registry ID
    NCT03951831
    Conditions
    Prostate Cancer Metastatic
    Interventions
    REGN2810; Degarelix; Leuprolide Acetate; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-05-16
    Completion
    2028-04
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    InterventionREGN2810; Degarelix; Leuprolide Acetate; Docetaxel
    PhasePhase 2
    Registry statusActive not recruiting